ADiTx Therapeutics, Inc., a life sciences company, focuses on developing nucleic acid-based technologies for addressing the rejection of transplanted organs, autoimmune diseases, and allergies. The company is developing Apoptotic DNA Immunotherapy (ADi), a nucleic acid-based technology that utilizes an approach, which mimics the way the body naturally induces tolerance to its own tissues. It also develops ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was founded in 2017 and is headquartered in Loma Linda, California.

ADiTx Therapeutics, Inc.

ADiTx Therapeutics, Inc., a life sciences company, focuses on developing nucleic acid-based technologies for addressing the rejection of transplanted organs, autoimmune diseases, and allergies

Should you buy, sell, or hold ADiTx Therapeutics, Inc. (ADTX) ?

ADiTx Therapeutics, Inc. (ADTX) : Buy or Sell